Alligator Bioscience: ATOR-1017 pre-clinical data support a best-in-class 4-1BB antibody profile
- Unique binding profile and cross-linking properties- Oral presentation at Protein Engineering Summit in Boston, USLund, Sweden, 3 May 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, will present pre-clinical data for the drug candidate ATOR-1017 at the Protein Engineering Summit (PEGS) 14th Annual Meeting in Boston, US. ATOR-1017 is a monoclonal antibody that activates the costimulatory receptor 4-1BB expressed on T cells in the tumor area and is being developed for